Collectively, these results identify VEGF as a central regulator of the vascular-immune axis during cytotoxic EGFR+αCD40 therapy in GBM and provide a strong rationale for combining vascular-, tumor-, and immune-targeted approaches to overcome therapeutic resistance and improve outcomes for patients with GBM. Here, VEGFA is linked to glioblastoma.